This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising.
Redwood AI (CSE: AIRX)(OTCQB: RDWCF)(Frankfurt: Y0N, WKN: A422EZ), a developer of artificial intelligence-powered chemical synthesis technology, announced the addition of Chemical AI Risk Evaluator (“CARE”), a reaction-safety screening and decision-support feature within its Reactosphere platform. CARE is designed to help chemists identify potential safety concerns earlier in the synthesis planning process by consolidating Safety Data Sheet (“SDS”) information, Globally Harmonized System (“GHS”) hazard indicators, structural alerts and reaction-specific safety findings into a single profile. The feature incorporates a custom, chemist-curated rule framework to evaluate chemical identities, reagent and condition combinations and potential reaction hazards, providing severity assessments and recommendations for further review.
CARE also integrates with Reactosphere’s retrosynthesis workflow, enabling users to compare proposed synthetic routes based on potential safety risks, flagged chemicals and required review efforts. Safety profiles can be exported as PDF documents for recordkeeping and further evaluation. The company said the addition strengthens Reactosphere’s capabilities in chemical synthesis planning and safety-aware decision support across multiple industries. CARE is intended as a preliminary screening tool and does not replace qualified chemist or environmental, health and safety review before operational use.
To view the full press release, visit https://ibn.fm/8pjGL
About Redwood AI Corp.
Redwood AI is a technology company developing advanced artificial intelligence and cybersecurity solutions for defence, public safety and life sciences. The Company applies artificial intelligence across quantum cybersecurity, scientific research and advanced chemistry applications. Redwood AI’s technology is designed to help organizations prepare for quantum-enabled cybersecurity threats while enabling faster, more efficient development of new therapies and chemistry-driven applications.
NOTE TO INVESTORS: The latest news and updates relating to RDWCF are available in the company’s newsroom at https://ibn.fm/RDWCF
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN